Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...

The USA compounding pharmacies market is on track for significant growth, estimated to reach USD 5,156.2 million in 2024, with projections indicating a compound annual growth rate (CAGR) of 7.8% ...

Tirzepatide and semaglutide both belong to a class of drugs known as GLP-1s. Compounding pharmacies have been producing copycat versions of the drugs while they have been in short supply.

The FDA declined to comment. The Outsourcing Facilities Association, which brought the lawsuit along with a Texas compounding pharmacy did not immediately respond to requests for comment.

They license and monitor pharmacies, pharmacy chains, compound pharmacies, blood storage units in hospitals, and medical stores in government health facilities, which are limited to storage ...

Semaglutide, one of several appetite suppressing drugs called GLP-1s, helped dampen her "food noise." Several of Dunham's family members are also on GLP-1s, and their Thanksgiving food bill is ...

DUBLIN--(BUSINESS WIRE)--The "U.S. Compounding Pharmacy Market - Industry Outlook & Forecast 2024-2029" report has been added to ResearchAndMarkets.com's offering. The U.S. compounding pharmacies ...

"FDA continues to monitor supply and demand for these products." Since the shortage began, specialty and compounding pharmacies have been allowed to sell off-brand versions of the weight loss drug.